Article
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
Scientific reports - 6 Apr 2022
Messina Vincenzo, Nevola Riccardo, Izzi Antonio, De Lucia Sposito Pellegrino, Marrone Aldo, Rega Roberto, Fusco Raffaele, Lumino Paolina, Rinaldi Luca, Gaglione Pasqualina, Simeone Filomena, Sasso Ferdinando Carlo, Maggi Paolo, Adinolfi Luigi Elio
Abstract excerpt
SARS-CoV-2 is still a health problem worldwide despite the availability of vaccines. Therefore, there is a need for effective and safe antiviral. SARS-CoV-2 and HCV necessitate RNA-dependent RNA polymerase (RdRp) for replication; therefore, it has been hypothesized that RdRp inhibitors used to treat HCV may be effective treating SARS-CoV-2. Accordingly, we evaluated the effect of the sofosbuvir/velpatasvir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.